Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database

References

• Ng AK. Diffuse large B-cell lymphoma. Semin Radiat Oncol. 2007;17:169–175.
   PubMed Web of Science ®Google Scholar
• Martelli M, Ferreri AJ, Agostinelli C, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol/Hematol. 2013;87:146–171.
   PubMed Web of Science ®Google Scholar
• Howlader NN, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD; 2017. [cited 2019 May 28]. Available from: https://seer.cancer.gov/csr/1975_2014/, Table 19.26: All Lymphoid Neoplasms with Detailed Non-Hodgkin Lymphoma Subtypes; SEER Incidence Rates and Annual Percent Change by Age at Diagnosis, All Races, Both Sexes, 2005 – 2014.
   Google Scholar
• Freedman AS, Aster JC [Internet]. Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma. UptoDate. [cited 2019 Jan 1]. Available from: https://www.uptodate.com/contents/epidemiology-clinical-manifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma.
   Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA: Cancer J Clin. 2006;56(2):106–130.
   PubMed Web of Science ®Google Scholar
• Ries L, Harkins D, Krapcho M, et al. SEER cancer statistics review,1975 to 2003. Bethesda, MD: National Cancer Institute; 2006.
   Google Scholar
• Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684–1692.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas Version3.2016 [Internet]. 2016. [cited 2019 Jan 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
   Google Scholar
• Morrison VA. Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma. Expert Rev Anticancer Ther. 2008;8:1651–1658.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Satram-Hoang S, Reyes C, et al. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist. 2014;19:1249–1257.
   PubMed Web of Science ®Google Scholar
• Williams JN, Rai A, Lipscomb J, et al. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. 2015;121:1800–1808.
   PubMed Web of Science ®Google Scholar
• Vincent GK, Velkoff VA. The Next Four Decades: The Older Population in the United States: 2010 to 2050. Population Estimates and Predictions. [cited 2018 Oct 19]. Available from: census.gov/prod/2010pubs/p25-1138.pdf
   Google Scholar
• Overview of the SEER Program. Available from: https://seer.cancer.gov/about/overview.html [cited 2019 May 10].
   Google Scholar
• Documentation for MEDPAR files. [cited 2019 May 28]. Available from: https://healthcaredelivery.cancer.gov/seermedicare/medicare/MEDPAR.pdf2018
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676–682.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Khan NF, Perera R, Harper S, et al. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract. 2010;11:1.
   PubMed Web of Science ®Google Scholar
• Broder MS, Quock TP, Chang E, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017;10:366–374.
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Farnia S, Crawford S, et al. Standardization of terminology for episodes of hematopoietic stem cell patient transplant care. Biol Blood Marrow Transplant. 2013;19:851–857.
   PubMed Web of Science ®Google Scholar
• Boslooper K, Kibbelaar R, Storm H, et al. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leukemia Lymphoma. 2014;55:526–532.
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Stenson M, Werlenius O, et al. Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Leukemia Lymphoma. 2012;53:394–399.
   PubMed Web of Science ®Google Scholar
• Varga C, Holcroft C, Kezouh A, et al. Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study. Leukemia Lymphoma. 2014;55:533–537.
   PubMed Web of Science ®Google Scholar
• Lin TL, Kuo MC, Shih LY, et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol. 2012;91:1383–1391.
   PubMed Web of Science ®Google Scholar
• Fenske TS, Hamadani M, Cohen JB, et al. Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-hodgkin lymphoma: increasingly successful application to older patients. Biol Blood Marrow Transplant. 2016;22:1543–1551.
   PubMed Web of Science ®Google Scholar
• Fenske TS, Ahn KW, Graff TM, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016;174:235–248.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Boumendil A, Finel H, et al. The impact of advanced patient age on mortality after allogeneic hematopoietic cell transplantation for non-hodgkin lymphoma: a retrospective study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party. Biol Blood Marrow Transplant. 2018;25:86–93.
   PubMedGoogle Scholar